Table 13.
Intervention | Strategy | Patient population | Phase | Year | Results | ClinicalTrials.gov identifier |
---|---|---|---|---|---|---|
CP-870,893 + Gemcitabine. | Monoclonal antibody and cytotoxic drugs | Pancreatic neoplasms | I | 2013 | Overall survival 8.4 months Progression-free survival 5.3 months | NCT00711191 |
CP-870,893 + Gemcitabine | Monoclonal antibody and cytotoxic drugs | PDAC | I | 2014 | Pending | NCT01456585 |
CP-870,893 | Monoclonal antibody | Advanced solid tumors | I | 2014 | Pending | NCT02225002 |